scholarly journals Antineoplastic effects of erufosine on Graffi myeloid tumour in hamsters

2021 ◽  
Vol 24 (3) ◽  
pp. 442-449
Author(s):  
R. A. Toshkova ◽  
K. S. Todorova ◽  
R. D. Tzoneva
Keyword(s):  
Tumour Growth ◽  
Anticancer Agent ◽  
Experimental Therapy ◽  
Drug Candidate ◽  
The Novel ◽  
Tumour Growth Inhibition ◽  
Metastatic Activity ◽  
Antitumour Effects ◽  
Significant Health ◽  
Tumour Transplantation

Cancer has become one of the most significant health challenges for both human and veterinary medicine. The present study examined the antineoplastic and antimetastatic activity of the novel membrane-targeting anticancer agent erufosine. The antitumour effects of erufosine on Graffi virus-induced experimental myeloid tumour in hamsters was assessed by histopathological methods and evaluation of some biometric parameters of tumour growth. Two schemes of experimental antitumour therapy were applied - one that started simultaneously with the tumour transplantation and a second one that started after the appearance of palpable tumours. The results demonstrated protective antitumour effect of erufosine, expressed by decrease of transplantability, tumour growth inhibition, suppression of metastatic activity and extension of mean survival time. The effectivity of the experimental therapy was more pronounced when it was started simultaneously with the transplantation of the tumour cells. Presented results suggest that erufosine is a promising drug candidate for treatment of haematological malignances.

scholarly journals Tumour growth inhibition and anti‐metastatic activity of a mutated furin‐resistant Semaphorin 3E isoform

2012 ◽  
Vol 4 (3) ◽  
pp. 234-250 ◽  
Author(s):  
Andrea Casazza ◽  
Boaz Kigel ◽  
Federica Maione ◽  
Lorena Capparuccia ◽  
Ofra Kessler ◽  
...  
Keyword(s):  
Growth Inhibition ◽  
Tumour Growth ◽  
Tumour Growth Inhibition ◽  
Metastatic Activity

scholarly journals The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models

2015 ◽  
Vol 46 (6) ◽  
pp. 2335-2345 ◽  
Author(s):  
JUAN GARONA ◽  
MARINA PIFANO ◽  
ULISES D. ORLANDO ◽  
MARIA B. PASTRIAN ◽  
NANCY B. IANNUCCI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumour Growth ◽  
The Novel ◽  
Cancer Models

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients

2002 ◽  
Vol 13 (8) ◽  
pp. 807-814 ◽  
Author(s):  
HJG Desirée van den Bongard ◽  
Dick Pluim ◽  
Hilde Rosing ◽  
Lianda Nan-Offeringa ◽  
Margaret Schot ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Pharmacokinetic Study ◽  
Anticancer Agent ◽  
The Novel ◽  
Excretion Balance

FEATURES OF THE COURSE AND TACTICS OF MANAGING CHILDREN WITH KIDNEYS AND URINARY TRACT DISEASES DURING THE PANDEMIC OF NEW CORONAVIRUS INFECTION COVID-19

2021 ◽  
Vol 100 (4) ◽  
pp. 74-79
Author(s):  
I.M. Kagantsov ◽  
◽  
V.V. Sizonov ◽  
V.G. Svarich ◽  
K.P. Piskunov ◽  
...  
Keyword(s):  
Age Groups ◽  
Clinical Manifestations ◽  
Routine Care ◽  
The Novel ◽  
Urinary System ◽  
Death Rates ◽  
Global Pandemic ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Significant Health

The novel coronavirus infection (SARS-CoV-2), which first appeared in Wuhan, China in December 2019, has been declared a global pandemic by WHO. COVID-19 affects people of all age groups. The disease in children is usually asymptomatic or mild compared to adults, and with a significantly lower death rates. Data on kidney damage in children with COVID-19, as well as the effect of coronavirus infection on the course of diseases of the genitourinary system, are limited, the risks of contracting a new coronavirus infection in children with significant health problems, including those with chronic kidney disease, remain uncertain. The pandemic has affected the activities of surgeons treating diseases of the urinary system in children. Since the prospects for the end of the pandemic are vague, it is necessary to formulate criteria for selecting patients who can and should be provided with routine care in the pandemic. The purpose of this review is to highlight the features of the clinical manifestations and treatment of children with COVID-19, occurring against the background of previous renal pathology or complicating its course.

scholarly journals Monocytes mediate Salmonella Typhimurium‐induced tumour growth inhibition in a mouse melanoma model

2021 ◽  
Author(s):  
Síle A. Johnson ◽  
Michael J. Ormsby ◽  
Hannah M. Wessel ◽  
Heather E. Hulme ◽  
Alberto Bravo‐Blas ◽  
...  
Keyword(s):  
Growth Inhibition ◽  
Salmonella Typhimurium ◽  
Tumour Growth ◽  
Mouse Melanoma ◽  
Mouse Melanoma Model ◽  
Melanoma Model ◽  
Tumour Growth Inhibition

scholarly journals Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions

Parasite ◽  
2021 ◽  
Vol 28 ◽  
pp. 22 ◽  
Author(s):  
Eric Tielemans ◽  
Tomoko Otsuki ◽  
Tara Cheesman ◽  
Fiona Selmes ◽  
Anthony Pfefferkorn ◽  
...  
Keyword(s):  
United States ◽  
Field Studies ◽  
The United States ◽  
Positive Control ◽  
Control Group ◽  
The Novel ◽  
Domestic Cats ◽  
Label Dose ◽  
Treatment Tolerance ◽  
Significant Health

Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies.

scholarly journals Chiral Resolution, Absolute Configuration Assignment, and Genotoxicity Evaluation of Racemic 3,4-Dihydroquinazoline as a Novel Anticancer Agent

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Junseong Ahn ◽  
Dohyeong Ko ◽  
Seyoung Yang ◽  
Kwang H. Moon ◽  
Jiwon Woo ◽  
...  
Keyword(s):  
Absolute Configuration ◽  
Anticancer Agent ◽  
Metabolic Activation ◽  
Chiral Resolution ◽  
Drug Candidate ◽  
Bacterial Strains ◽  
Configuration Assignment ◽  
Preclinical And Clinical Studies ◽  
Human A549 ◽  
A549 Lung

If a new drug candidate will be a mixture of enantiomers, both enantiomers should be separately studied for at least latent genotoxicity as early as possible since the thalidomide tragedy. Our group has recently reported that KCP-10043F (OZ-001) as a racemate (±)-3,4-dihydroquinazoline derivative strongly represses the proliferation of human A549 lung cancer cells by caspase-mediated apoptosis via STAT3 inactivation. To investigate the possible teratological effects of the two enantiomers of a racemic KCP-10043F, therefore chiral resolution of (±)-KCP-10043F was performed and subsequently followed by a series of chemical processes to afford the corresponding chiral diastereomers. By using 1H NMR anisotropy method, the absolute configuration (+)-KCP-10043F and (−)-KCP-10043F could be assigned as S and R configuration, respectively. The bacterial reverse mutation test (Ames test) for racemate (±)-KCP-10043F and its two enantiomers exhibited that all three stereoisomers were found to be nongenotoxic against five bacterial strains with/without metabolic activation. In addition, (R)-(−)-KCP-10043F displayed almost equal anticancer activity to (S)-(+)-KCP-10043F against three cancer cell lines. Based on these overall results, racemate KCP-10043F (OZ-001) could be used for our ongoing preclinical and clinical studies without the expensive asymmetric process and/or chiral separation.

Sign in / Sign up

Export Citation Format

Share Document